RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
From article in thread (paraphrase) Among hospitalized COVID-19 pts w/ hypertension, inpatient use of ACEI/ARB assoc w/ lower risk of all-cause mortality ... need to consider residual confounders, but unlikely that in-hospital use of ACEI/ARB assoc w/ i
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @rincondesisifo: (Circulation) Uso de IECA y ARA2 en pac con HTA y #COVID19 hospitalizados y riesgo de mortalidad https://t.co/iRkVpyypE…
(Circulation) Uso de IECA y ARA2 en pac con HTA y #COVID19 hospitalizados y riesgo de mortalidad https://t.co/iRkVpyypEx Est Observ https://t.co/6AbbiLEW47
They’re starting to test the Untested Mechanistic Hypothesis
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
U r seriously quoting a study that has 99.9% of the info from Wuhan doctors? Yea ok lol
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
Registro que informa una menor mortalidad en pacientes COVID e hipertensos que fueron hospitalizados. Mas datos a favor de NO suspender IECA/ARA2... continuará... #COVID19argentina
@faisalislam We need short term effective therapeutic intervention too. https://t.co/gDZZmkjgyJ
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
IEC et ARA2 protecteurs ?
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7% died Not on one: 9.8% died New in @CircRes: https://t.co/fh7vympZeB
RT @DrVikasKapil: More grist to the mill. It appears it is #hypertension and #CVD risk factors, rather than specific medication classes tha…
Possible therapeutic intervention.
Apparent protective effect of ACE inhibitors for covid in this observational study https://t.co/EIfoTZwWj4
This is helpful......... thank you.
More grist to the mill. It appears it is #hypertension and #CVD risk factors, rather than specific medication classes that is associated with poorer outcomes in #COVID19. @DrKatPollock #arb #ace #raas
RT @MartinFierro769: IEC sartans. Une étude chinoise sur 1128 patients hypertendus hospitalisés dont 188 sous traitement par IEC sartans, q…
RT @emrkar: Covid_19 da ACEI ve ARB ler hastalığa bağlı mortaliteyi azaltabilir https://t.co/pSkmZY3mJT
RT @MartinFierro769: IEC sartans. Une étude chinoise sur 1128 patients hypertendus hospitalisés dont 188 sous traitement par IEC sartans, q…
RT @MartinFierro769: IEC sartans. Une étude chinoise sur 1128 patients hypertendus hospitalisés dont 188 sous traitement par IEC sartans, q…
IEC sartans. Une étude chinoise sur 1128 patients hypertendus hospitalisés dont 188 sous traitement par IEC sartans, qui dément le rôle délétère de ces traitements sur la mortalité toutes causes chez les patients Covid19+. Etudes à poursuivre.
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
NCT04338009 is looking at this too "Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID)" https://t.co/GYXSPYsRiE
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
Kafa karıştırmıyor mu biraz?
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/WiTTb5dPX5
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @Anesthrunner: Pacientes hospitalizados que toman IECAs y ARAs por hipertensión crónica, tiene mejor pronóstico. Mortalidad 3.7 Vs 9.8%…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @drjosflynn: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortalit…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @drjosflynn: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortalit…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @tyonarock: ACEI/ARBの使用とCOVID-19の予後との関係 中国からの報告 1128人のCOVID-19陽性高血圧患者 188人ACEI/ARBの使用:3.7%死亡 940人ACEI/ARBの不使用:9.8%死亡 有意差ありという結果 https…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
Im just happy angiotensin receptor blockers are showing real promise for saving COVID19 patients! https://t.co/UjnnRAdpmf
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
(yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.co/NdtcWYPJS1 https://t.co/VCgKtNUfMk
RT @drjosflynn: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortalit…
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
RT @drjosflynn: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortalit…
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
RT @crr1114: @asouth_neph @MattFrieman @MackayIM Your site is great. And thanks for linking this article earlier: https://t.co/A9x0boB9no
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
كنت بتسأل عن الأخ Ace ياأحمد @__iAhmadd
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/urL47BlBZq @edgarvlermamd @ClinicaN
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/aBzai9fLAc
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
Among patients with hypertension hospitalized with COVID-19, inpatient treatment with ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. https://t.co/zRE33CQM0b
RT @emrkar: Covid_19 da ACEI ve ARB ler hastalığa bağlı mortaliteyi azaltabilir https://t.co/pSkmZY3mJT
RT @emrkar: Covid_19 da ACEI ve ARB ler hastalığa bağlı mortaliteyi azaltabilir https://t.co/pSkmZY3mJT
Covid_19 da ACEI ve ARB ler hastalığa bağlı mortaliteyi azaltabilir https://t.co/pSkmZY3mJT
IEC et ARA2 protecteurs? https://t.co/EwQ1zI6S6f
Aksini düşünen var mıydı?? #CoronavirusLockdown #CoronavirusOutbreak https://t.co/vE0jUxLAmI
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
ACEI do not worsen outcomes in #COVID19 patients . All such claims earlier in the course of #COVID19 pandemic are falling one after the other. Stick to science do not change long proven Management based on claims or case reports !! https://t.co/ARlFW3BgdC
Will be fascinated when this is 'over' to better understand how some pops w/existing comorbidities--including tobacco users being underrepresented in hospitalizations--fared 'better' than others, esp in hospital settings.
@__philipn__ @VectorSting @RogerAlvarezDO Check it out guys - published yesterday. Finally data suggesting ARB usage might be very protective! https://t.co/Ku8PevGTuZ
RT @JohnNosta: ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associa…
ACE Inhibitors and #COVID19. Among hospitalized COVID-19 patients with #hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. https://t.co/wH5VfMte6n #coronavirus @MikeAlbertMD
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…
This interesting... and opposite to what I assumed https://t.co/OC7PoZNZX6
And they are also studying whether Losartan (the angiotensin blocker I take for my blood pressure) can help the virus from spreading. Great news especially as someone who is on this drug, knowing I’m possibly at lower risk because my drug may actually help
This new study concludes: "...associated with lower risk of all-cause mortality compared with ACEI/ARB non-users... unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk." https://t.co/bCFp4Dmo9t
RT @DanielJDrucker: Association Nation #COVID19 “Lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did no…
RT @asouth_neph: Better study design and analytic methods, will be up on @NephJC site Inpatient Use of #ACEi and #ARB and Mortality Amo…